Satoshi Ebata
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Usefulness of rituximab for the treatment of systemic sclerosis-associated interstitial lung disease: Further analysis of the DESIRES trial.
Journal: Journal of the American Academy of Dermatology
Published: November 15, 2024
Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: machine-learning analysis of the DESIRES trial.
Journal: Rheumatology (Oxford, England)
Published: October 21, 2024
Autoantibody landscape and functional role of anti-C-C motif chemokine receptor 8 autoantibodies in systemic sclerosis: post-hoc analysis of a B-cell depletion trial.
Journal: Nature communications
Published: August 05, 2024
Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels.
Journal: JAMA dermatology
Published: February 15, 2023
Significance of anti-transcobalamin receptor antibodies in cutaneous arteritis revealed by proteome-wide autoantibody screening.
Journal: Journal of autoimmunity
Published: January 04, 2023
Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: Analysis of a single-arm, open-label, phase 1 trial.
Journal: Journal of the American Academy of Dermatology
Published: October 18, 2022
New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics.
Journal: Journal of clinical medicine
Published: July 15, 2022
Involvement of B cells in the development of systemic sclerosis.
Journal: Frontiers in immunology
Published: May 08, 2022
Serum C-X-C Chemokine Ligand 1 Levels in Patients with Systemic Sclerosis: Relationship of Clinical and Laboratory Observations to Anti-CD20 Monoclonal Antibody Administration.
Journal: Life (Basel, Switzerland)
Published: March 30, 2022
Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status.
Journal: Frontiers in immunology
Published: March 10, 2022
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial.
Journal: The Lancet. Rheumatology
Published: February 08, 2022
Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study.
Journal: Diagnostics (Basel, Switzerland)
Published: October 25, 2021
Last Updated: 09/26/2026